封面
市場調查報告書
商品編碼
1449642

全球 Bracamesin 市場:按給藥途徑、按應用、按分銷管道、按地區

Global Blarcamesine Market, By Route of Adminsitration, By Application, By Distribution Channel, By Geography .

出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2026年,全球Bracamesin市場價值將達到8.222億美元,預計2031年將達到9.924億美元,2026年至2031年的年複合成長率為3.8%。

報告範圍 報告詳情
基準年 2023年 2023/2024年市場規模 8.222 億美元
實際資料 2019-2023 預測期 2026-2031
預測期間2023/2024 至2030/2031年年複合成長率: 3.80% 2030/2031價值預測 9.924 億美元
圖 1. Bracamesin全球市場佔有率(%),依地區分類,2026年
全球布拉卡馬辛市場-IMG1

Blarcamesine 是細胞內 sigma-1Chaperone蛋白的促效劑。具體來說,它是混合的σ1/毒蕈鹼受體配體。 sigma 1受體在大多數組織中表達,位於粒線體和內質網之間的局部接觸處,與許多其他膜受體形成異二聚體,產生多種細胞路徑,並影響生理過程。據報導,Blarcamesine 在高奈米莫耳範圍內與 sigma-1 受體結合,在低微莫耳範圍內與毒蕈鹼受體結合。據報道,這種化合物在接受毒蕈鹼受體拮抗劑東莨菪鹼、合成 AB寡聚物注射液和 NMDA 受體促效劑地佐西平治療的小鼠中表現出記憶保留和神經保護作用(Villard 等) AB 使用寡聚物注射模型的其他研究表明,Blarcamesine可能抑制Tau過度磷酸化並保護粒線體。

市場動態:.

政府批准的增加預計將在預測期內推動市場成長。例如,2023年12月19日,開發治療神經退化性疾病和神經發育障礙的差異化療法的臨床階段生物製藥公司Anavex Lifesciences宣布,歐洲藥品管理局(European Medicines Agency)人類使用醫藥產品委員會( EMA 內的CHMP)宣布,已同意用於治療阿茲海默症的口服 Blarcamesine 有資格根據歐洲藥品管理局的集中程序在歐盟提交行銷核准申請。

本研究的主要特點

  • 本報告對全球 Bracamesin 市場進行了詳細分析,並介紹了以2023年為基準年的預測期(2026-2031)的市場規模和年複合成長率(CAGR %)。
  • 揭示了各個細分市場的潛在商機,並為該市場說明了一系列有吸引力的投資提案。
  • 提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
  • 根據公司亮點、產品系列、主要亮點、財務表現和策略等參數,介紹了全球 Blarcamesine 市場的主要企業。
  • 本報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 全球Blarcamesine市場報告針對該行業的各個相關人員,如投資者、供應商、產品製造商、經銷商、新進入者和財務分析師。
  • 相關人員可以透過分析全球Blarcamesine市場時所使用的各種策略矩陣來促進決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map(COM)

第3章 市場動態、法規及趨勢分析

  • 市場動態
  • 主要亮點
  • 監管場景
  • 最近的趨勢
  • PEST分析
  • 波特的分析
  • 合併、收購和合作

第4章 全球 Blarcamesine 市場 - 冠狀病毒(COVID-19)大流行的影響

  • 新型冠狀病毒感染疾病(COVID-19)的流行病學
  • 供需面分析
  • 經濟影響

第5章 全球 Bracalcamesin 市場,依給藥途徑,2019-2031

  • 口服
  • 胃腸外

第6章 全球黑色攝影機市場,依應用分類,2019-2031

  • 阿茲海默症
  • 帕金森氏症
  • 失智症
  • 雷特氏症候群
  • 其他

第7章 全球黑機市場,2019-2031

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球黑來機市場,依地區,2019-2031

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 歐洲其他地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 競爭格局

  • 公司簡介
    • Anavex Life Sciences

第10章

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6655

Global blarcamesin market will be valued at US$ 822.2 Mn in 2026 and is expected to reach US$ 992.4 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.8% from 2026 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 822.2 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2026 to 2031.
Forecast Period 2023/2024 to 2030/2031 CAGR: 3.80% 2030/2031 Value Projection: US$ 992.4 Mn
Figure 1. Global Blarcamesine Market Share (%), By Region, 2026
Global Blarcamesine Market - IMG1

Blarcamesine is an agonist of the intracellular sigma-1 chaperone protein. Specifically, it is a mixed ligand for sigma1/muscarinic receptors. Expressed in most tissues and located at focal contacts between mitochondria and the endoplasmic reticulum, the sigma-1 receptor forms heterodimers with many other membrane receptors and, as such, influences multiple cellular pathways and physiological processes. Blarcamesine reportedly binds the sigma-1 receptor in the high nanomolar and the muscarinic receptor in the low micromolar range. The compound has been reported to have memory-preserving and neuroprotective effects in mice treated with the muscarinic receptor antagonist scopolamine, with synthetic AB oligomer injection, or with the NMDA receptor agonist dizocilpine (Villard et al., 2011). Other studies in the AB oligomer injection model suggest that blarcamesine may block tau hyperphosphorylation and protect mitochondria.

Market Dynamics:

Increasing government approval is expected to drive the growth of the market over the forecast period. For instance, on December 19, 2023, Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, announced that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) agreed that oral blarcamesine for Alzheimer's disease is eligible for submission of an application for a Union Marketing Authorization in the EU under the European Medicines Agency's centralized procedure.

Key features of the study:

  • This report provides in-depth analysis of the global blarcamesine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global blarcamesine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Anavex Life Sciences
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global blarcamesine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blarcamesine market

Detailed Segmentation:

  • Global Blarcamesine Market, By Route of Administration
    • Oral
    • Parentral
  • Global Blarcamesine Market, By Application
    • Alzheimer's Disease
    • Parkinson's Disease
    • Dementia
    • Rett Syndrome
    • Others
  • Global Blarcamesine Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Blarcamesine Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Top Companies in the Global Blarcamesine Market:
    • Anavex Life Sciences

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Blarcamesine Market, By Route of Administration
    • Global Blarcamesine Market, By Application
    • Global Blarcamesine Market, By Distribution Channel
    • Global Blarcamesine Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing research and development activities
    • Strict regulatory requirements
    • Emerging markets
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • PEST Analysis
  • PORTER's Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Blarcamesine Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Blarcamesine Market, By Route of Administration, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031(%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Blarcamesine Market, By Application, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031(%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Alzheimer's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Parkinson's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Dementia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Rett Syndrome
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Blarcamesine Market, By , 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031(%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Blarcamesine Market, By Region, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031(%)
    • Y-o-Y Growth Analysis, For Region,
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profile
    • Anavex Life Sciences
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us